Insight Molecular Diagnostics (IMDX) Gains from Investment Securities (2015 - 2026)

Insight Molecular Diagnostics has disclosed Gains from Investment Securities across 12 years of filings, most recently posting $3652.0 for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $3652.0, down 99.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $3652.0 (down 99.96% YoY), and the FY2025 annual result was $2.3 million, up 119.33% from the prior year.
• Gains from Investment Securities came in at $3652.0 for Q1 2026 at Insight Molecular Diagnostics, down from $1.3 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $17.3 million in Q4 2022 to a low of -$18.3 million in Q1 2023.
• The 5-year median for Gains from Investment Securities is $879000.0 (2025), against an average of $1.5 million.
• Across the five-year window, Gains from Investment Securities sank 2015.36% in 2022 and jumped 2297.52% in 2024, its largest moves.
• Insight Molecular Diagnostics' Gains from Investment Securities stood at $17.3 million in 2022, then plunged by 35.2% to $11.2 million in 2023, then plunged by 185.74% to -$9.6 million in 2024, then soared by 113.5% to $1.3 million in 2025, then tumbled by 99.72% to $3652.0 in 2026.
• The last three Gains from Investment Securities figures came in at $3652.0 (Q1 2026), $1.3 million (Q3 2025), and $2.8 million (Q2 2025), per Business Quant data.